PCSK9抗体;PCSK9 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Human rectal cancer tissue, Jurkat cells, HT29 cells, Primary antibody: P12032(PCSK9 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies represent a breakthrough in lipid-lowering therapy, targeting a key regulator of cholesterol metabolism. Discovered in 2003. PCSK9 binds to hepatic LDL receptors (LDLR), promoting their degradation and reducing LDL cholesterol (LDL-C) clearance. Gain-of-function PCSK9 mutations correlate with hypercholesterolemia and cardiovascular risk, while loss-of-function variants link to lifelong LDL-C reduction and cardioprotection. This established PCSK9 as a therapeutic target.

Developed through monoclonal antibody technology, PCSK9 inhibitors (e.g., alirocumab, evolocumab) block PCSK9-LDLR interaction, stabilizing LDLR expression and enhancing LDL-C uptake. Clinical trials demonstrated 50-60% LDL-C reduction, even in statin-resistant patients, with corresponding decreases in cardiovascular events. Approved since 2015. these injectable biologics fill critical gaps in managing familial hypercholesterolemia and high-risk atherosclerotic patients.

Despite efficacy, challenges include high costs and subcutaneous administration. Ongoing research explores oral PCSK9 inhibitors and gene-silencing approaches (inclisiran). PCSK9 antibodies exemplify translational success, bridging genetic insights to targeted therapy, reshaping preventive cardiology paradigms through precision lipid management. Their development underscores the importance of molecular pathway characterization in addressing residual cardiovascular risk.